groove

Penn Center for AIDS Research

David H. Henry

faculty photo
Clinical Professor of Medicine (Hematology-Oncology)
Director, AIDS Malignancy Program, University of Pennsylvania Cancer Center, Philadelphia, PA
Vice Chairman, Department of Medicine, Pennsylvania Hospital, Philadelphia, PA
Associate Program Director, Department of Medicine, Pennsylvania Hospital, Philadelphia, PA
Education Officer, Department of Medicine, Pennsylvania Hospital
Penn Medicine Clinician, Pennsylvania Hospital
Department: Medicine

Contact information
Penn Hematology/Oncology
Abramson Cancer Center
Pennsylvania Hospital, Farm Journal Building
230 West Washington Square
Philadelphia, PA 19106
Office: 215-829-6088
Fax: 215-829-6104
Education:
B.A.
Princeton University, 1970.
M.D.
University of Pennsylvania School of Medicine, 1975.
Post-Graduate Training
Intern in Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, 1975-1976.
Resident in Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, 1976-1978.
Fellowship, Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, 1978-1981.
Chief Medical Resident, Hospital of the University of Pennsylvania, Philadelphia, PA, 1979-1980.
Certifications
American Board of Internal Medicine, 1978.
American Board of Internal Medicine-Hematology, 1980.
American Board of Internal Medicine-Medical Oncology, 1981.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Selected Publications

Gina Nicholson 1, Katherine B Carlson 2, Rohini K Hernandez 2, Jennifer Schenfeld 2, Benoit Cadieux 3, David Henry 4, Vitor Jose De Sousa Barbosa 3, Hossam Saad 3: Treatment Patterns of Bone-targeting Agents Among Solid Tumor Patients with Bone Metastases. American Journal of Clinical Oncology January 2024.

David Henry: CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor-Mutated Advanced Non-Small-Cell Lung Cancer. Practice Update December 2023.

Lakshmi Rajdev MD, MS, Chia-Ching Jackie Wang MD, Himanshu Joshi MBBS, MPH, MSc, PhD, Shelly Lensing MS, Jeannette Lee PhD, Juan Carlos Ramos MD, Robert Baiocchi MD, PhD, Lee Ratner MD, PhD, Paul G. Rubinstein MD, Richard Ambinder MD, PhD, David Henry MD, Howard Streicher MD, Richard F. Little MD, MPH, Elizabeth Chiao MD, MPH, Dirk P. Dittmer PhD, Mark H. Einstein MD, MS, Ethel Cesarman MD, PhD, Ronald Mitsuyasu MD, Joseph A. Sparano MD: Assessment of the safety of nivolumab in people living with HIV with advanced cancer on antiretroviral therapy: the AIDS Malignancy Consortium 095 Study. American Cancer Society Journals November 2023.

Paul G Rubinstein, MD, Page C Moore, PhD, Milan Bimali, PhD, Jeanette Y Lee, PhD, Michelle A Rudek, PhD, Amy Chadburn, MD, Lee Ratner, MD, David H Henry, MD, Ethel Cesarman, MD, Camille E DeMarco, MPH, Dominique Costagliola, PhD, Yassine Taoufik, PhD, Juan Carlos Ramos, MD, Elad Sharon, MD, Erin G Reid, MD, Richard F Ambinder, MD, Ronald Mitsuyasu, MD, Nicolas Mounier, MD, Caroline Besson, MD, Ariela Noy, MD for the AIDS Malignancy Consortium and the Lymphoma Study Association † : Brentuximab vedotin with AVD for stage II–IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trial. The Lancet 10(8): E624-E632, August 2023.

David Henry: A commentary on: Circulating Tumor DNA Following Neoadjuvant Chemotherapy and Surgery in ER-Positive and HER2-Negative Breast Cancer. Practice Update June 2023.

David Henry: A Commentary On: Adjuvant Osimertinib for Resected EFGR-Mutated Stage Ib-IIIA NSCLC. Practice Update June 2023.

David Henry: A commentary on: Nivolumab Plus Brentuximab Vedotin for Low-Risk Relapsed Classic Hodgkin Lymphoma. Practice Update June 2023.

David Henry: A Commentary On: Neoadjuvant Chemoradiation for Treatment of LARC. Practice Update June 2023.

John A. Glaspy, Nashat Y Gabrail, Patricia A. Locantore-Ford, Gopal C Saha, Elise Hardy, Tyson Lee, Katharina Modelska, David H. Henry: Open‐label, Phase 2 study of roxadustat for the treatment of anemia in patients receiving chemotherapy for non‐myeloid malignancies. Journal of Clinical Oncology January 2023.

David Henry: 2022 Top Story in Oncology: Durvalumab Plus Gemcitabine and Cisplatin as First-Line Treatment for Advanced Biliary Tract Cancer. Practice update December 2022.

back to top
Last updated: 02/25/2024
The Trustees of the University of Pennsylvania